Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis
- 93 Downloads
Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44μg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and magnetic resonance imaging in clinical trials. A significant efficacy advantage for subcutaneous interferon-β-1a three times weekly over intramuscular interferon-β-1a 30μg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-β-1a 44μg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat relapsing-remitting multiple sclerosis. 1 This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2005; 65 (9): 1295-312. Reviewers of the original full text article are listed in the Acknowledgments section. 2 The use of trade names is for product identification purposes only and does not imply endorsement.
KeywordsExpand Disability Status Scale Glatiramer Acetate Glatiramer Rebif Median Treatment Duration
The full text article in Drugs 2005; 65 (9): 1295–312 was reviewed by: C. Gasperini, Department of Neuroscience, S. Camillo-Forlanini Hospital, Rome, Italy; R.M. Herndon, Department of Neurology, G.V. (Sonny) Montgomery Department of Veterans Affairs Medical Center, Jackson, Mississippi, USA; D.D. Miksikostas, Department of Neurology, Athens Naval Hospital, Athens, Greece; H.S. Panitch, Neurology Health Care Service, University of Vermont, College of Medicine, Burlington, Vermont, USA; P.S. Sorensen, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.
- 1.Serono, Inc. Rebif (interferon-beta-1a) sc injection: prescribing information. Rock-land (MA): Serono, Inc., 2004Google Scholar
- 6.Randomised double-blind placebo-controlled study of interferon β-la in relapsing/ remitting multiple sclerosis: PRISMS (Prevention of Relapses and disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139): 1498-504Google Scholar
- 9.PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001 Jun 26; 56 (12): 1628-36Google Scholar
- 13.Paty D. Long-term observational efficacy and safety follow-up of the PRISMS cohort [abstract no. P555 plus poster]. 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2003 Sep 17–20; MilanGoogle Scholar
- 19.Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004 Sep; 251Suppl. 5: v/42–9Google Scholar
- 21.Beresniak A, Coyle P, Vollmer T, et al. Cost-benefit and cost-effectiveness analyses of interferon beta-1a therapies for multiple sclerosis [abstract no. P414 plus poster]. 13th Annual Meeting of the European Neurological Society; 2003 Jun 14–18; IstanbulGoogle Scholar